<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<doc>
  <docno>
    <textblock>FR940202-2-00099</textblock>
  </docno>
  <parent>
    <textblock>FR940202-2-00071</textblock>
  </parent>
  <text>
    <textblock>7. Large-volume nebulizers and mist tents</textblock>
    <textblock>8. Other Devices</textblock>
    <textblock>B. Interruption of Person-to-Person Transmission of Bacteria</textblock>
    <textblock>1. Handwashing</textblock>
    <textblock>2. Barrier Precautions</textblock>
    <textblock>3. Care of Patients with Tracheostomy</textblock>
    <textblock>4. Suctioning of Respiratory Tract Secretions</textblock>
    <textblock>III. Modifying Host Risk for Infection</textblock>
    <textblock>A. Precautions for Prevention of Endogenous Pneumonia</textblock>
    <textblock>1. Prevention of Aspiration</textblock>
    <textblock>2. Prevention of Gastric Colonization</textblock>
    <textblock>B. Prevention of Postoperative Pneumonia</textblock>
    <textblock>C. Other Prophylactic Procedures for Pneumonia</textblock>
    <textblock>1. Vaccination of Patients</textblock>
    <textblock>2. Systemic Antimicrobial Prophylaxis</textblock>
    <textblock>3. Use of Rotating ``Kinetic'' Beds</textblock>
    <textblock>Prevention and Control of Legionnaires' Disease</textblock>
    <textblock>I. Staff Education and Infection Surveillance</textblock>
    <textblock>A. Staff Education</textblock>
    <textblock>B. Surveillance</textblock>
    <textblock>II. Interruption of Transmission of</textblock>
    <textblock>Legionella</textblock>
    <textblock>spp.</textblock>
    <textblock>A. Primary Prevention (Preventing Nosocomial Legionnaires' Disease when No Cases have been Documented)</textblock>
    <textblock>1. Nebulization and Other Devices</textblock>
    <textblock>2. Cooling Towers</textblock>
    <textblock>3. Water-Distribution System</textblock>
    <textblock>B. Secondary Prevention (Response to Identification of Laboratory-Confirmed Nosocomial Legionellosis)</textblock>
    <textblock>Prevention and Control of Nosocomial Pulmonary Aspergillosis</textblock>
    <textblock>I. Staff Education and Infection Surveillance</textblock>
    <textblock>A. Staff Education</textblock>
    <textblock>B. Surveillance</textblock>
    <textblock>II. Interruption of Transmission of</textblock>
    <textblock>Aspergillus</textblock>
    <textblock>spp. Spores</textblock>
    <textblock>A. Planning New Specialized-Care Units for High-Risk Patients</textblock>
    <textblock>B. In Existing Facilities with no Cases of Nosocomial Aspergillosis</textblock>
    <textblock>C. When a Case of Nosocomial Aspergillosis Occurs</textblock>
    <textblock>III. Modifying Host Risk for Infection</textblock>
    <textblock>Prevention and Control of Respiratory Syncytial Virus (RSV)</textblock>
    <textblock>I. Staff Education and Infection Surveillance</textblock>
    <textblock>A. Staff Education</textblock>
    <textblock>B. Surveillance</textblock>
    <textblock>II. Interruption of Transmission of RSV</textblock>
    <textblock>A. Prevention of Person-to-Person Transmission</textblock>
    <textblock>1. Primary Measures for Contact Isolation</textblock>
    <textblock>a. Handwashing</textblock>
    <textblock>b. Gloving</textblock>
    <textblock>c. Gowning</textblock>
    <textblock>d. Staffing</textblock>
    <textblock>e. Limiting Visitors</textblock>
    <textblock>2. Control of RSV Outbreaks</textblock>
    <textblock>a. Use of Private Room, Cohorting, and Patient-Screening</textblock>
    <textblock>b. Personnel Cohorting</textblock>
    <textblock>c. Postponing Patient Admission</textblock>
    <textblock>d. Wearing Eye-Nose Goggles</textblock>
    <textblock>Prevention and Control of Influenza</textblock>
    <textblock>I. Staff Education and Infection Surveillance</textblock>
    <textblock>A. Staff Education</textblock>
    <textblock>B. Surveillance</textblock>
    <textblock>II. Modifying Host Risk for Infection</textblock>
    <textblock>A. Vaccination</textblock>
    <textblock>1. Patients</textblock>
    <textblock>2. Personnel</textblock>
    <textblock>B. Use of Antiviral Agents</textblock>
    <textblock>III. Interruption of (Person-to-Person) Transmission</textblock>
    <textblock>IV. Control of Influenza Outbreaks</textblock>
    <textblock>A. Determining the Outbreak Strain</textblock>
    <textblock>B. Vaccination of Patients and Personnel</textblock>
    <textblock>C. Amantadine or Rimantadine Administration</textblock>
    <textblock>D. Interruption of (Person-to-Person) Transmission</textblock>
  </text>
</doc>
